Pituitary Stalk Interruption Syndrome (PSIS) Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global Pituitary Stalk Interruption Syndrome (PSIS) Market is Segmented By Treatment (Hormone Replacement, Genetic Counseling), By End-User (Hospitals, Specialty Clinics, Academic and Research Institutes, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Pituitary Stalk Interruption Syndrome (PSIS) Market Overview

Global Pituitary Stalk Interruption Syndrome (PSIS) Market is expected to reach at a high CAGR during the forecast period 2023-2030.

The global pituitary stalk interruption syndrome market witnessing growth and transformations in recent years, with various factors influencing its dynamics such as increasing prevalence, rising awareness, and others. The global market is placing increasing emphasis on reducing its impact. The pituitary stalk interruption syndrome is a rare type of syndrome, also known as pituitary stalk transection syndrome, and is mainly characterized by an absent or hypoplastic anterior pituitary gland, thin or absent infundibulum, and ectopic posterior pituitary location.

The primary treatment of this syndrome includes hormone replacement such as growth hormone, hydrocortisone, thyroxine, and at puberty stage sex steroids replacement. Genetic counseling is also used for the treatment but in very rare conditions. Similarly, North America dominates the market, capturing the largest market share owing to the region’s favorable reimbursement policies, and advanced healthcare infrastructure. The cause of this condition is unknown. The condition can expected to be caused due to rare genetic changes in the HESX1, LHX4, OTX2, SOX3, and PROKR2 genes.

Owing to increasing awareness about the condition, rising clinical trials, increasing demand for novel therapeutics due to unmet needs, and advancements in treatment options are the major factors expected to drive the global market over the forecast period. However, limited treatment options, lack of funding and investments for further research activities are the factors expected to hamper the growth of the market over the forecast period.

Pituitary Stalk Interruption Syndrome (PSIS) Market Scope

For more details on this report Request for Sample

Pituitary Stalk Interruption Syndrome (PSIS) Market Dynamics

Increasing Awareness is Expected to Drive the Growth of the Market

The increasing awareness about the condition is expected to drive the growth of the market over the forecast period. Increasing awareness can helps to manage the symptoms in the early stages and also helps to seek better treatment without further complications. The increased awareness of this condition among the general public and healthcare professionals can lead to earlier and more accurate diagnoses with better patient outcomes. 

For instance, according to the National Institute of Health (NIH), Increasing medical awareness on PSIS clinical and endocrine heterogeneity may help in a more early and accurate diagnosis. Corroboration of neuroimaging and endocrine data will improve knowledge and understanding and also it will create the premises for molecular diagnosis, genetic counseling, and better patient management with appropriate and better treatment results.

Moreover, with increasing awareness, affected individuals and their families may actively seek medical attention and treatment options with early detection of symptoms. This increased demand for healthcare services and therapies can stimulate growth in the market. With improved awareness, it becomes more feasible to recruit participants for clinical trials aimed at developing new treatments or improving existing ones. This can lead to the advancement of therapies and potentially expand the market.

Increasing Prevalence is Also Expected to Drive the Growth of the Market

The increasing prevalence is also expected to drive the growth of the market over the forecast period. In recent years and in past years the prevalence has been very low and is expected to increase in upcoming years due to lifestyle changes and genetic conditions. The exact cause of this condition is unknown, so controlling the rising prevalence is by better treatment. As medical knowledge and diagnostic capabilities improve, it results in more cases with accurate diagnosis. 

Furthermore, if this condition can be detected through newborn screening programs or genetic testing, this could lead to earlier diagnosis and intervention, potentially increasing the reported prevalence and the need for treatment. Increased prevalence can attract more research funding and clinical trials focused on PSIS, potentially leading to the development of new and more effective treatment options.

For instance, According to the National Institute of Health (NIH), PSIS is a rare clinical entity with an incidence of 0.5/100,000. Lately, more cases of PSIS are being recognized, after the use of MRI as a primary radiological modality in patients with panhypopituitarism. The mean age at the time of diagnosis is 9.4 ± 11.6 years. It is expected to increase the prevalence in upcoming years. Interestingly, male predominance has also been reported with a male-to-female ratio of 2.3-6.9:1.0, suggesting X-linked inheritance. The incidence of breech delivery, cesarean section, and neonatal distress are high in the PSIS population. 

Limited Treatment Options are Expected to Hamper the Market's Growth

The limited treatment options associated with the condition are expected to hamper the growth of the market over the forecast period. The only treatment for pituitary stalk interruption syndrome is hormone replacement such as growth hormone, hydrocortisone, and thyroxine replacements. This rare type of disease is expected to affect a very small number of individuals due to some genetic conditions. This limited patient population less attractive for pharmaceutical companies to invest in research and development for new treatments.

Additionally, developing the new treatments needs excessive funding and investments, due to the lack of funding and investments, the treatment options are less likely to develop and the developed therapies are more costly. This cost can be a barrier to the development of new therapies. Due to the small patient population, there may be a lack of financial incentives for pharmaceutical companies to develop new drugs or therapies. This can result in a shortage of treatment options.

Pituitary Stalk Interruption Syndrome (PSIS) Market Segmentation Analysis

The global pituitary stalk interruption syndrome market is segmented based on treatment, end-user and region.

The Hormone Replacement Segment Accounted for Approximately 38% of the Pituitary Stalk Interruption Syndrome Market Share

The hormone replacement segment is expected to hold the largest market share over the forecast period. Hormone replacement is considered a primary treatment which includes growth hormone, hydrocortisone, thyroxine, and sex steroid replacement. Hormone replacement is highly effective in replenishing deficient hormones in the body. It can effectively helps to manage the symptoms and improve the overall well-being of individuals with PSIS which is mainly characterized by hormone deficiencies. 

For instance, according to the National Institute of Health (NIH), Myxedema coma is the most severe, life-threatening effect of severe hypothyroidism, which is characterized by PSIS. Hormone replacement therapy is the most commonly used treatment for PSIS. Hypothyroidism leads to PSIS, then the hormone replacement can helps the patients to manage the symptoms and be considered as a better and primary treatment.

Moreover, in the hormone replacement process, the type of hormone, dosage, and administration method can be adjusted based on individual hormone levels. This treatment helps to provide rapid relief from symptoms such as growth delay, fatigue, and some reproductive problems, which are associated with hormone deficiencies. This treatment process has been considered the best treatment for decades due to its safety and efficacy measures.

Global Pituitary Stalk Interruption Syndrome (PSIS) Market Geographical Share

North America Accounted for Approximately 39% of the Market Share in 2022, Owing to the Advanced Healthcare Infrastructure and Favourable Reimbursement Policies

North America region is expected to hold the largest market share over the forecast period owing to the advanced healthcare infrastructure and favorable reimbursement policies. North America region is well-known for its advanced healthcare infrastructure including advanced hospitals to manage the symptoms in a better way, and treatment of the disease by using advanced therapies such as hormone replacement, specialty clinics, research, and academic institutes to perform better research to develop innovative treatment options. 

This advanced healthcare infrastructure helps to increase the awareness in the general public about this rare type of disease to early detection and diagnosis by observing the symptoms in early stages for better treatment.

For instance, according to the National Organization for Rare Disorders, Inc., awareness about PSIS disorder helps to identify the symptoms in the early stages. Signs and symptoms of this condition includes, in newborns include low blood sugar levels (hypoglycemia), jaundice, congenital abnormalities, and small penis (micropenis) and/or testis that are not in the scrotal sac (cryptorchidism). Later in childhood, signs may include short stature, seizures, low arterial pressure (hypotension), and/or intellectual delay. Some people can also have vision problems (septooptic dysplasia) and Fanconi anemia.

Furthermore, North America offers favorable reimbursement policies to patients for effective treatment to manage the symptoms in a better way. The improved insurance coverage offers the better treatment for many patients at affordable costs, leading to market dominance in the region.

Pituitary Stalk Interruption Syndrome (PSIS) Market Companies

The major global players in the pituitary stalk interruption syndrome market include AnkeBio Co., Ltd, Hoffmann-La Roche Limited, Novo Nordisk, Pfizer Inc., Omicron Pharma, LEXICARE PHARMA PVT. LTD., Ferring Pharmaceuticals, EMD Serono, Inc., Ralington Pharma and Symbiotec Pharmalab among others. 

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for pharmaceutical industries worldwide, including the global pituitary stalk interruption syndrome market. During the pandemic, research activities on this condition have been temporarily postponed due to the redirected focus on the COVID-19 pandemic research and its related restrictions.

The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular check-ups, appointments, and consultations worldwide, this can also leads to further complications associated with pituitary stalk interruption syndrome. Many hospitals are focused on COVID-19 cases, which reduces the pituitary stalk interruption syndrome treatment.

Moreover, the COVID-19 pandemic severely disrupted global supply chains, impacting the transportation of raw materials such as growth hormone products and other hormone products. Movement restrictions and border closures delayed shipments and caused drug transportation delays. Additionally, some countries faced shortages of products for treatment due to disruptions in their supply chain networks.

DataM Intelligence Opinion:

According to the DataM Intelligence, pituitary stalk interruption syndrome (PSIS) is a rare genetic type of congenital pituitary anatomical defect. The market is expected to experience growth in the coming years due to its increasing prevalence of genetic conditions, and ongoing clinical trials for novel therapeutic innovations which are expected to offer better patient outcomes. 

Moreover, due to the rarity of the condition, the increasing awareness is expected to drive the growth of the market over the forecast period, some clinical trials are going on for the development of therapeutics for enhanced treatment. Due to the limited treatment options, the market growth is expected to hamper. 

Why Purchase the Report?

• To visualize the global pituitary stalk interruption syndrome market segmentation based on treatment, end-user and region as well as understand key commercial assets and players
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of pituitary stalk interruption syndrome market-level with all segments
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study
• Product mapping available as excel consisting of key products of all the major players

The global pituitary stalk interruption syndrome market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies